**Supplementary Table I: Laboratory parameters including immune cell diagnostic at different time points after SARS-CoV-2 diagnosis**.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Laboratory parameter** | **Range** | **d+1** | **d+6** | **d+11** | **d+21** | **d+29** | **d+44** | **d+56** | **d+82** | **d+148** | **d+174** |
|  |  | **LEN withdrawn** | **LEN resumed** |  |
| IL-6 | < 7 pg/ml | **12.6 +** | **26.5 +** | 1.6 | 1.7 | n.d. | 3.8 | n.d. | n.d. | n.d. | n.d. |
| CRP | < 0.5 mg/dl | **2.8 +** | **6.96 +** | **0.17 +** | 0.05 | 0.06 | 0.1 | 0.05 | 0.08 | 0.67 | 0.07 |
| D-Dim | < 500 ng/ml | 420 | **569 +** | 326 | n.d. | 346 | n.d. | n.d. | n.d. | n.d. | n.d. |
| LDH | < 248 U/l | 214 | **278 +** | 200 | 166 | 195 | 179 | 180 | n.d. | n.d. | n.d. |
| WBC | 3.92-9.81/nl | **2.05 -** | **2.67 -** | **3.05 -** | **1.96 -** | **3.36 -** | 4.04 | **2.2 -** | **2.01** | 4.83 | **2.42** |
| **Neutrophils** | 1.78-6.23/nl | **1.16 -** | 1.8 | 2.02\* | **0.98 -** | **1.6 -** | 2.53 | **1.08 -** | **1.24** | 3.37 | **1.09** |
| **Monocytes** | 0.26-0.87/nl | 0.28 | **0.16 -** | 0.33 | 0.26 | 0.48 | 0.53 | 0.36 | 0.27 | 0.47 | 0.28 |
| **Lymphocytes** | 1.05-3.24/nl | **0.57 -** | **0.12 -** | **0.56 -** | **0.62 -** | 1.052  | **0.77 -** | **0.54 -** | **0.37** | **0.52** | **0.51** |
| CD3+ | 700-2100/µl | **422 -** | n.d. | **366 -** | **408 -** | **627 -** | **492 -** | **365 -** | **207 -** | **318 -** | **333 -** |
| CD3+CD4+ | 300-1400/µl | **74 -** | n.d. | **108 -** | **97 -** | **149 -** | **129 -** | **101 -** | **100 -** | **85 -** | **130 --** |
| CD3+CD8+ | 200-900/µl | 324 | n.d. | 233 | 287 | 438 | 340 | 244 | **101** - | 214 | **119 -** |
| B cells CD19+ | 100-500/µl | n.d. | n.d. | **89 -** | **92 -** | 167 | 133 | 115 | **99** - | **84** - | **79 -** |
| NK cellsCD56+CD3- | 90-600|µl | n.d. | n.d. | **69 -** | **67 -** | **81 -** | 117 | **86 -** | **78 -** | 114 | **73 -** |
| Anti-SARS-CoV2 IgG (EIA, routine laboratory) | qualitative | n.d. | n.d. | **+** | **+** | **+** | **+** | **+** | **+** | **+** | **+** |
|  |  **CD4+ T helper cell subsets** |  |
| Naive CD4+ *CD4+CD45RA+CD62L+* | 121-456/µl | n.d. | n.d. | **14 --** | **13 --** | **21 --** | **8 --** | **2 --** | **2 --** | **3 --** | **2 --** |
| Effector memory CD4+ *CD4+CD45RO+CD62L-* | 59-321/µl | n.d. | n.d. | **16 -** | **14 -** | **42 -** | **17 -** | **22 -** | **13 -** | **8 -** | **15 -** |
| Central memory CD4+ *CD4+CD45RO+CD62L+* | 92-341/µl | n.d. | n.d. | **86 -** | **72 -** | **89 -** | 107 | **76 -** | **86 -** | **76 -** | 115 |
| T regs *CD4+CD25bright +CD127dim* | 25-180/µl | n.d. | n.d. | **17 -** | **10 -** | **15 -** | **19 -** | **15 -** | **17 -** | **14 -** | **17 -** |
|  |  **CD8+ cytotoxic T cell subsets** |  |
| Naive CD8+ *CD8+CD45RA+CD62L+* | 86-257/µl | n.d. | n.d. | **24 -** | **32 -** | **57 -** | **24 -** | **11 -** | **7 -** | **17 -** | **18 -** |
| Effector memory CD8+ *CD8+CD45RO+CD62L-* | 15-162/µl | n.d. | n.d. | 133 | 155 | **241 +** | **200 +** | 152 | 50  | 119  | 87 |
| Central memory CD8+ *CD8+CD45RO+CD62L+* | 19-93/µl | n.d. | n.d. | 81 | 93 | **128 +** | **119 +** | 66 | 44 | 88 | 74 |
|  |  **T cell activation** |  |
| Early activated CD4+ *CD4+CD69+* | 0-70/µl | n.d. | n.d. | 1 | 1 | 2 | 1 | 1 | 1 | 1 | n.d. |
| Early activated CD8+ *CD8+CD69+* | 0-90/µl | n.d. | n.d. | 7 | 6 | 14 | 5 | 2 | 1 | 5 | n.d. |
| Late activated CD4+ *CD4+HLA-DR+* | 0-70/µl | n.d. | n.d. | 38 | 31 | 43 | 58 | 42 | 43 | 34 | n.d. |
| Late activated CD8+ *CD8+HLA-DR+* | 0-90/µl | n.d. | n.d. | **219 +** | **260 +** | **378 +** | **322 +** | **227 +** | 90 | **194 +** | n.d. |

*\*after G-CSF as on day +8 the neutrophils were 0.5/µl; LEN = lenalidomide; n.d. = not done*